Prosecution Insights
Last updated: May 29, 2026

Examiner: RIGA, MICHAEL ANGELO

Tech Center 1600 • Art Units: 1633 1634

This examiner grants 52% of resolved cases

Performance Statistics

51.8%
Allow Rate
-8.2% vs TC avg
92
Total Applications
+63.5%
Interview Lift
1504
Avg Prosecution Days
Based on 56 resolved cases, 2023–2026

Rejection Statute Breakdown

0.5%
§101 Eligibility
3.2%
§102 Novelty
61.0%
§103 Obviousness
25.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17309403 AAV VIRAL VECTORS AND USES THEREOF Non-Final OA NOVARTIS AG
17430086 MESENCHYMAL STEM CELL SHEET AND USE THEREOF Final Rejection BOE TECHNOLOGY GROUP CO., LTD.
18035021 LIVE CELL ASSAY FOR PROTEASE INHIBITION Non-Final OA Regents of the University of Minnesota
17998330 COMPOSITIONS USEFUL IN TREATMENT OF KRABBE DISEASE Final Rejection The Trustees of the University of Pennsylvania
17789314 Method for Producing Serum for Culturing Mammalian Cells Non-Final OA NIPRO CORPORATION
17434513 RECOMBINANT VECTORS COMPRISING ARYLSULFATASE A AND THEIR USES IN STEM CELL THERAPY FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY Non-Final OA VERSITECH LIMITED
18556593 ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES Non-Final OA University of Miami
17260443 PLURIPOTENT STEM CELL-DERIVED PLATE-SHAPED CARTILAGE AND METHOD FOR PRODUCING THE SAME Final Rejection KYOTO UNIVERSITY
17309207 REGENERATIVE ABSCOPAL EFFECTS Non-Final OA Figene, LLC
17917198 B7-H3 CHIMERIC ANTIGEN RECEPTORS Non-Final OA St. Jude Children's Research Hospital, Inc.
16990185 NON-HLA RESTRICTED T CELL RECEPTORS AND USES THEREOF Non-Final OA MEMORIAL SLOAN-KETTERING CANCER CENTER
18258778 METHOD FOR PRODUCING OLIGODENDROCYTES Non-Final OA Koji TANABE
18212404 USE OF PROSTAGLANDIN E2 (PGE2)-PRIMED MESENCHYMAL STEM CELL (MSC) PRODUCT IN PREPARATION OF DRUG FOR TREATING LUNG INJURY (LI) Non-Final OA NANKAI UNIVERSITY
18285180 MEDIUM COMPOSITION FOR CULTURING MUSCLE STEM CELL COMPRISING CURCUMIN LONGA, GLYSIN, OR INSULIN FOR PROLIFERATION OF MUSCLE STEM CELL Non-Final OA DANAGREEN CO., LTD.
16970216 COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DELIVERY Non-Final OA FLAGSHIP PIONEERING INNOVATIONS V, INC.
17997377 METHOD TO PRODUCE T CELLS AND USES THEREOF Non-Final OA OSPEDALE SAN RAFFAELE S.R.L.
17414425 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE OCULAR DISEASES Final Rejection Massachusetts Ear and Eye Infirmary
17047945 METHOD FOR MONITORING THE VIABILITY OF A GRAFT Non-Final OA HEMARINA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month